Actively Recruiting
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-04-08
80
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a new approach for men with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy and have no PSA progression. This phase II randomized trial is embedded within an ongoing cancer radiotherapy registry and aims to see if adding metastasis-directed radiotherapy (MDRT) to standard systemic therapy can improve outcomes such as PSA response and failure-free survival. Participants will be randomly assigned either to receive MDRT targeting metastatic sites visible on PSMA-PET scans after starting systemic therapy, or to continue with standard systemic therapy alone, with or without standard radiotherapy if needed. If after the initial MDRT the PSA level remains above 0.2 ng/mL at 3 months, a repeat PSMA-PET scan will be done and a second MDRT course will be offered to consolidate residual disease. Throughout the study, patients will be followed for oncologic outcomes and side effects. Key measurements include PSA response at 12 months and failure-free survival over 3 years, with additional assessments of quality of life, toxicity, and time to progression extending up to 5 years. The study is open-label, with neither patients nor doctors blinded to treatment assignment, and will continue until July 2030.
CONDITIONS
Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of active MDRT or continuation of systemic therapy as per standard care
Participants receive metastasis directed radiotherapy (MDRT) to PSMA-PET visible disease or continue systemic therapy per standard of care.
Visits as scheduled for radiotherapy or systemic therapy
Duration - Up to 5 years
Participants are monitored for treatment response, toxicity, quality of life, and disease progression.
Regular follow-up visits as per study schedule
Total: 1 location
1
CRCHUM
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
M
Mom Phat
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Philippe Giguère, Houda Bahig, Sydney Westra...
https://pubmed.ncbi.nlm.nih.gov/42032732